Approximately 5,000 cases of acute lymphoblastic leukemia are diagnosed annually in children and adolescents in Europe. With current treatment, approximately 80% of T-ALL and 90% of B-ALL can be cured, but the treatment is lengthy and has significant side effects. Our research project aims to develop more effective and less toxic combination and immunological therapies. We are searching for and optimizing new drug treatments targeting the signaling pathways of B- and T-cell receptors and the metabolism of leukemia cells. We harness the body’s own immune system to enhance treatment response and use multidimensional data as a patient-specific map for an AI model that predicts treatment outcomes. The project’s results aim to reduce treatment-related side effects, improve the prognosis of leukemia, and increase knowledge of the disease’s biology.

2024